PMA supplement

P010031 S317: MAXIMO II DF-4, MAXIMO II, DF-4, PROTECTA DF-4, PROTECTA ICD, PROTECTA XT DF-4, PROTECTA XT ICD, SECURA DF-4, SECURA IC

FDA PMA supplement · 30-Day Notice · Medtronic Cardiac Rhythm Disease Management

Key facts

Original PMA P010031
Supplement number S317
Supplement type 30-Day Notice
Reason for the supplement Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name MAXIMO II DF-4, MAXIMO II, DF-4, PROTECTA DF-4, PROTECTA ICD, PROTECTA XT DF-4, PROTECTA XT ICD, SECURA DF-4, SECURA IC
Applicant Medtronic Cardiac Rhythm Disease Management
Received date Jul 3, 2012
Decision date Aug 1, 2012

At a glance

  • No Expedited review granted
  • No Approval order on file
  • No Summary of safety and effectiveness on file

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA supplements

A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA supplements